TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stroke Team Remote Evaluation Using a Digital Observation Camera Arizona - The Initial Mayo Clinic Experience
Brief Summary: Noninvasive prospective multi-center study of an interactive 2-way, wireless or site-independent, audiovisual telemedicine system designed for real-time remote examination of acute stroke symptoms and deficits as a basis for treatment consultation and recommendation.

Study aims (1) to determine the impact of a site-independent, remote, telemedicine consultation system on decision making in the Emergency Department, regarding the decision to treat or not to treat with thrombolytics; (2) to assess the numbers of patients who receive thrombolytics and the time to treatment in patients evaluated by telemedicine versus telephone only; (3) to assess the appropriateness of thrombolytic treatment decisions in telemedicine versus telephone-only consultations; and (4) to assess the completeness of the data collection in telemedicine versus telephone-only consultations.

60 patients in Arizona with acute presentation of stroke symptoms, per bedside practitioner discretion (onset generally less than 12 hours and likely less than 3 hours)

Two arms: Video Camera/Telemedicine (Intervention n = 30) and No Video Camera/Telephone only (Control n = 30)


Options:
A: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Two way audio/video telemedicine consult | Intervention Type: OTHER; Name: Telephone; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Two way audio/video telemedicine consult; Assigned to Arm(s): 2
C: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Drug: Stepped care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Stepped care; Assigned to Arm(s): Stepped Care
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Web-based care management | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Telephone and face-to-face care management | Arm Label: Arm 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Internet access alone | Intervention Type: PROCEDURE; Name: Web-based care management; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Telephone and face-to-face care management; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Internet access alone; Assigned to Arm(s): Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment
Brief Summary: To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.


Options:
A: Arm Label: Prophylaxis, high dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: Prophylaxis, low dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: On-demand (trial duration 28 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, high dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, low dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): On-demand (trial duration 28 weeks)
B: Arm Label: Recombinant Factor VIII prophylaxis treatment; Type: EXPERIMENTAL; Interventions: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Arm Label: Recombinant Factor VIII on-demand treatment; Type: EXPERIMENTAL; Interventions: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Intervention Type: BIOLOGICAL; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Recombinant Factor VIII prophylaxis treatment | Intervention Type: BIOLOGICAL; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Recombinant Factor VIII on-demand treatment
C: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
D: Arm Label: BAY94-9027 / Adynovi; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Arm Label: Adynovi / BAY94-9027; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Intervention Type: BIOLOGICAL; Name: Damoctocog-alfa-pegol (BAY94-9027, Jivi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi | Intervention Type: BIOLOGICAL; Name: Rurioctocog alfa pegol (Adynovi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Exacerbation of Chronic Heart Failure: "Hospital at Home" Versus Inpatient Care for Elderly Patients. A Randomized, Controlled Trial.
Brief Summary: Aim of the study was to evaluate the efficacy of hospital-at-home treatment compared with inpatient care in selected elderly patients with acute exacerbation of chronic heart failure (CHF).


Options:
A: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group
B: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Treatment of elderly patients in GHHS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment of elderly patients in a GMW | Intervention Type: OTHER; Name: Treatment of elderly patients in a GMW; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Treatment of elderly patients in GHHS; Assigned to Arm(s): 1
D: Arm Label: Inpatient hospitalization; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional inpatient hospitalization | Arm Label: Home hospitalization; Type: EXPERIMENTAL; Interventions: Other: Home hospitalization | Intervention Type: OTHER; Name: Home hospitalization; Assigned to Arm(s): Home hospitalization | Intervention Type: OTHER; Name: Traditional inpatient hospitalization; Assigned to Arm(s): Inpatient hospitalization

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial
Brief Summary: There is increasing evidence linking a fetal and early neonatal systemic inflammatory response syndrome to the subsequent development of bronchopulmonary dysplasia (BPD) and white matter injury (WMI) in very preterm infants. Babies with evidence of adrenal insufficiency early in life may not be able to control the inflammatory response and are thereby more likely to develop BPD than babies who do not show such evidence of inflammation. We designed a randomized controlled trial to test the hypothesis whether very preterm babies at high-risk of BPD, treated with low doses of HC during the first 10 days of life, are more likely to survive without BPD at 36 weeks of post-menstrual age (PMA), compared to babies treated with placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1: hydrocortisone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo
C: Arm Label: Dopamine and hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine, Drug: Hydrocortisone | Arm Label: Dopamine and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine, Drug: Syringe Placebo | Arm Label: Placebo and hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone, Drug: Infusion Placebo | Arm Label: Placebo and Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Infusion Placebo, Drug: Syringe Placebo | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine and hydrocortisone, Dopamine and placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Dopamine and hydrocortisone, Placebo and hydrocortisone | Intervention Type: DRUG; Name: Infusion Placebo; Assigned to Arm(s): Placebo and Placebo, Placebo and hydrocortisone | Intervention Type: DRUG; Name: Syringe Placebo; Assigned to Arm(s): Dopamine and placebo, Placebo and Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial
Brief Summary: There is increasing evidence linking a fetal and early neonatal systemic inflammatory response syndrome to the subsequent development of bronchopulmonary dysplasia (BPD) and white matter injury (WMI) in very preterm infants. Babies with evidence of adrenal insufficiency early in life may not be able to control the inflammatory response and are thereby more likely to develop BPD than babies who do not show such evidence of inflammation. We designed a randomized controlled trial to test the hypothesis whether very preterm babies at high-risk of BPD, treated with low doses of HC during the first 10 days of life, are more likely to survive without BPD at 36 weeks of post-menstrual age (PMA), compared to babies treated with placebo.


Options:
A: Arm Label: 1: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1: hydrocortisone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo
B: Arm Label: Infant treated with high dose ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Infant treated with high dose ibuprofen
C: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group
D: Arm Label: Early Treatment with cyclooxygenase inhibitors; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen, Drug: Indomethacin | Arm Label: Expectative Treatment; Type: SHAM_COMPARATOR; Interventions: Other: Expectative Management | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Early Treatment with cyclooxygenase inhibitors | Intervention Type: OTHER; Name: Expectative Management; Assigned to Arm(s): Expectative Treatment | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Early Treatment with cyclooxygenase inhibitors

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children
Brief Summary: The purpose of this study is to determine to what extent supplementation with zinc and other micronutrients are efficacious in preventing malaria in young Tanzanian children.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamins and minerals other than zinc | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamins plus zinc and other minerals | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamins and minerals other than zinc; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamins plus zinc and other minerals; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and vitamin A single dose at enrollment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo and vitamin A single dose at enrollment | Intervention Type: DRUG; Name: Zinc and vitamin A single dose at enrollment; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo and vitamin A single dose at enrollment; Assigned to Arm(s): 2
C: Arm Label: Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial.
Brief Summary: Hypothesis:Oral Voriconazole will be as effective as intravenous Amphotericin B as antifungal prophylaxis in induction of acute leukemia (ALL, AML) in pediatric patients, with less toxicity and more convenience.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Intervention Type: DRUG; Name: ORAL VORICONAZOLE and IV Amphotericin B; Assigned to Arm(s): 1, 2
B: Arm Label: Standard diagnostic strategy of culture and histology; Type: ACTIVE_COMPARATOR; Interventions: Other: Culture and histology | Arm Label: Aspergillus galactomannan and PCR directed; Type: EXPERIMENTAL; Interventions: Other: Aspergillus galactomannan and PCR | Intervention Type: OTHER; Name: Culture and histology; Assigned to Arm(s): Standard diagnostic strategy of culture and histology | Intervention Type: OTHER; Name: Aspergillus galactomannan and PCR; Assigned to Arm(s): Aspergillus galactomannan and PCR directed
C: Arm Label: High Risk Oncohematological Patients; Type: N/A; Interventions: Procedure: Aspergillus PCR technique, Procedure: Aspergillus AGA technique | Intervention Type: PROCEDURE; Name: Aspergillus PCR technique; Assigned to Arm(s): High Risk Oncohematological Patients | Intervention Type: PROCEDURE; Name: Aspergillus AGA technique; Assigned to Arm(s): High Risk Oncohematological Patients
D: Arm Label: Proven/Probable IA Patients; Type: N/A; Interventions: N/A | Arm Label: possible/No IA Patients; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study
Brief Summary: The risk of recurrence in stage III and IV of colorectal cancers (CRC) is high during the three years following the tumoral resection with curative aim. Therefore, a prolonged follow-up and an intense monitoring are recommended to detect these recurrences precociously. Nevertheless, current consensual morphological and biological examinations are not very contributory, of difficult interpretation and expensive. The metabolic imagery in tomoscintigraphy by emission of positron coupled with the scanner, called PET-TDM, allows to identify more specifically recurrences, analyzes the whole body, detects hepatic metastasis more precociously and give some benefice for early diagnosis of lymph nodes recurrence. The principle purpose of this study is to evaluate if the systematic follow-up per PET-TDM allows detecting more often recurrences accessible to a curative surgery. We make the hypothesis that the systematic practice of PET- tomodensitometry (TDM) during the follow-up of CRC allows to decrease non curative recurrences appearance during the 3 years follow-up after a curative surgery.


Options:
A: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: PET-TDM for current indication | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: semi-annual systematic PET-TDM | Intervention Type: OTHER; Name: semi-annual systematic PET-TDM; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: PET-TDM for current indication; Assigned to Arm(s): 2
C: Arm Label: Patient Directed; Type: OTHER; Interventions: Other: 'My Care Plan' | Arm Label: Clinician Directed; Type: OTHER; Interventions: Other: 'Survivorship Care Plan Builder' | Intervention Type: OTHER; Name: 'My Care Plan'; Assigned to Arm(s): Patient Directed | Intervention Type: OTHER; Name: 'Survivorship Care Plan Builder'; Assigned to Arm(s): Clinician Directed
D: Arm Label: 1 frequent control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Arm Label: 2 less frequent control; Type: OTHER; Interventions: Procedure: CT-scan, CEA, X-ray of lungs | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 1 frequent control | Intervention Type: PROCEDURE; Name: CT-scan, CEA, X-ray of lungs; Assigned to Arm(s): 2 less frequent control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Indacaterol 300 μg; Assigned to Arm(s): Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg capsules | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Indacaterol 150 μg capsules; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Indacaterol 300 μg capsules; Assigned to Arm(s): Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Indacaterol 150 μg and tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg | Arm Label: Tiotropium 18 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg, Tiotropium 18 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 μg
D: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Mental Stress Reduction in Defibrillator Patients
Brief Summary: The purpose of this study is to assess the effectiveness of a 10 week program of Stress Management versus control Patient Education sessions on cardiac responses to mental stress in veterans with Implantable Cardioverter-Defibrillators


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: Cognitive Behavioral Stress Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Stress Management (CBSM) | Arm Label: Patient Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Patient Education | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management (CBSM); Assigned to Arm(s): Cognitive Behavioral Stress Management | Intervention Type: OTHER; Name: Patient Education; Assigned to Arm(s): Patient Education
C: Arm Label: Web-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web-based multifactorial intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: Behavioral: web-based multifactorial intervention | Intervention Type: BEHAVIORAL; Name: web-based multifactorial intervention; Assigned to Arm(s): Usual care, Web-based behavioral intervention
D: Arm Label: CASA Intervention; Type: EXPERIMENTAL; Interventions: Other: CASA Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CASA Intervention; Assigned to Arm(s): CASA Intervention

Answer: B